UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000023
Receipt number R000000054
Scientific Title Multicenter phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma
Date of disclosure of the study information 2005/08/01
Last modified on 2010/01/12 12:27:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Acronym

Phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Scientific Title

Multicenter phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Scientific Title:Acronym

Phase II trial of neoadjuvant chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Region

Japan


Condition

Condition

oral squamous cell carcinoma

Classification by specialty

Oral surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Clinical and histopathological effect of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma

Key secondary outcomes

Safety of induction chemotherapy with docetaxel and nedaplatin for resectable oral squamous cell carcinoma


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Docetaxel (60 mg/m2) was administered intravenously for 1 h on day1. After completion of the docetaxel infusion, nedaplatin (100 mg/m2) was administered intravenously for another hour followed by 1,000 ml or more hydration.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) age between 20 and 75 years (patients aged >76 years were allowed if major organs functions was preserved), (2) Eastern Cooperative Oncology Group performance status (PS) score of 2 or less (3) adequate bone marrow function (4) adequate hepatic function (5) adequate renal function (6) Written informed consent

Key exclusion criteria

Patients were excluded if they had active infections, active second malignancy, severe heart diseases, interstitial pneumonia or lung fibrosis, severe pleural effusion or pericardial effusion that required drainage, fever more than or equal to 38 C, symptomatic brain metastasis, severe psychological disease, and possible pregnancy.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Etsuhide Yamamoto

Organization

Kanazawa University Graduate School of Medical Science

Division name

Oral & Maxillofacial Surgery

Zip code


Address

13-1 Takaramachi, Kanazawa, Ishikawa

TEL

076-265-2444

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Shinshu University School of Medicine

Division name

Department of Dentistry and Oral surgery

Zip code


Address

3-1-1 Asahi, Matsumoto, Nagano

TEL

0263-37-2675

Homepage URL


Email

hkurita@hsp.md.shinshu-u.ac.jp


Sponsor or person

Institute

Chubu research group on oral cancer

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 02 Month 06 Day

Date of IRB


Anticipated trial start date

2004 Year 06 Month 01 Day

Last follow-up date

2012 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2005 Year 07 Month 12 Day

Last modified on

2010 Year 01 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000054


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name